Equities research analysts expect Tivity Health (NASDAQ:TVTY) to announce $153.72 million in sales for the current quarter, according to Zacks Investment Research. Five analysts have provided estimates for Tivity Health’s earnings. The lowest sales estimate is $148.51 million and the highest is $156.00 million. Tivity Health reported sales of $140.97 million during the same quarter last year, which suggests a positive year-over-year growth rate of 9%. The firm is scheduled to issue its next quarterly earnings results after the market closes on Monday, April 23rd.
On average, analysts expect that Tivity Health will report full-year sales of $153.72 million for the current financial year, with estimates ranging from $614.10 million to $620.26 million. For the next year, analysts expect that the firm will post sales of $673.84 million per share, with estimates ranging from $649.92 million to $684.78 million. Zacks Investment Research’s sales calculations are an average based on a survey of research analysts that that provide coverage for Tivity Health.
Tivity Health (NASDAQ:TVTY) last issued its earnings results on Thursday, February 22nd. The company reported $0.41 earnings per share for the quarter, topping analysts’ consensus estimates of $0.32 by $0.09. Tivity Health had a return on equity of 29.17% and a net margin of 11.44%. The company had revenue of $139.40 million for the quarter, compared to analyst estimates of $138.22 million. During the same period in the prior year, the firm earned $0.35 earnings per share. Tivity Health’s revenue for the quarter was up 11.6% on a year-over-year basis.
TVTY has been the topic of a number of research reports. Zacks Investment Research raised Tivity Health from a “hold” rating to a “strong-buy” rating and set a $45.00 target price on the stock in a research report on Wednesday, February 28th. BidaskClub raised Tivity Health from a “hold” rating to a “buy” rating in a research report on Tuesday, March 6th. Chardan Capital reaffirmed a “neutral” rating and set a $41.00 target price (down from $44.00) on shares of Tivity Health in a research report on Friday, February 23rd. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $53.00 target price on shares of Tivity Health in a research report on Friday, February 23rd. Finally, Barrington Research upped their target price on Tivity Health from $40.00 to $47.00 and gave the stock an “outperform” rating in a research report on Friday, February 23rd. Two equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $46.88.
Shares of NASDAQ:TVTY traded up $0.20 during trading on Tuesday, reaching $39.45. 640,864 shares of the stock were exchanged, compared to its average volume of 493,800. Tivity Health has a 1-year low of $27.95 and a 1-year high of $48.50. The firm has a market capitalization of $1,571.50, a price-to-earnings ratio of 23.48, a PEG ratio of 1.66 and a beta of 0.31.
In related news, CEO Donato Tramuto sold 20,000 shares of the company’s stock in a transaction on Monday, April 2nd. The stock was sold at an average price of $39.30, for a total transaction of $786,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 8.42% of the company’s stock.
A number of institutional investors have recently made changes to their positions in TVTY. Nationwide Fund Advisors grew its holdings in Tivity Health by 20.4% during the third quarter. Nationwide Fund Advisors now owns 238,768 shares of the company’s stock worth $9,742,000 after buying an additional 40,492 shares in the last quarter. SG Americas Securities LLC bought a new stake in Tivity Health during the third quarter worth $210,000. Neuberger Berman Group LLC grew its stake in Tivity Health by 587.7% in the 3rd quarter. Neuberger Berman Group LLC now owns 1,633,016 shares of the company’s stock valued at $66,627,000 after purchasing an additional 1,395,539 shares during the period. Schwab Charles Investment Management Inc. grew its stake in Tivity Health by 27.3% in the 4th quarter. Schwab Charles Investment Management Inc. now owns 200,871 shares of the company’s stock valued at $7,342,000 after purchasing an additional 43,099 shares during the period. Finally, Mondrian Investment Partners LTD grew its stake in Tivity Health by 14.6% in the 4th quarter. Mondrian Investment Partners LTD now owns 106,766 shares of the company’s stock valued at $3,902,000 after purchasing an additional 13,607 shares during the period.
COPYRIGHT VIOLATION WARNING: This piece was reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this piece on another domain, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this piece can be read at https://ledgergazette.com/2018/04/18/brokerages-expect-tivity-health-tvty-will-announce-quarterly-sales-of-153-72-million.html.
About Tivity Health
Tivity Health, Inc provides fitness and health improvement programs in the United States. The company offers SilverSneakers senior fitness program to the members of Medicare advantage, Medicare supplement, and group retiree plans; and Prime fitness, a fitness facility access program through commercial health plans and employers.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tivity Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tivity Health and related companies with MarketBeat.com's FREE daily email newsletter.